Skip to main content

Table 2 Potentials of ZnONP nanocomposites on the liver function of EAC-challenged mice

From: Doxorubicin and folic acid-loaded zinc oxide nanoparticles-based combined anti-tumor and anti-inflammatory approach for enhanced anti-cancer therapy

Conjugates

ALT (U/L)

AST (U/L)

Naive

30.33 ± 5.50

95.67 ± 5.13

EAC

77.98 ± 0.57a

215.26 ± 9.39a

DOX

80.11 ± 5.55a

240.43 ± 8.97a,b

ZnONPs

47.47 ± 2.99a,b,c

298.13 ± 24.49

ZnONPs/DOX

62.26 ± 5.78a,b,c

347.60 ± 30.36a,b,c

ZnONPs/FA

58.94 ± 6.98a,b,c

244.76 ± 25.05a

ZnONPs/DOX/FA

60.20 ± 6.75a,b,c

237.87 ± 28.33a

  1. Data were represented as mean ± SD (n = 10). Difference between groups was considered statistically significant at P < 0.05. Note: a,b,c Statistically significant difference as compared to the corresponding means of naive group (a), EAC group (b), the DOX group (c)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us